Skip to main content

Published locations for Pralsetinib: Second drug for RET+ NSCLC approved in U.S.

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pralsetinib: Second drug for RET+ NSCLC approved in U.S.

User login

  • Reset your password
  • /content/pralsetinib-second-drug-ret-nsclc-approved-us
  • /oncologypractice/article/228173/lung-cancer/pralsetinib-second-drug-ret-nsclc-approved-us
  • /jcomjournal/article/228173/lung-cancer/pralsetinib-second-drug-ret-nsclc-approved-us
  • /hematology-oncology/article/228173/lung-cancer/pralsetinib-second-drug-ret-nsclc-approved-us
  • /chestphysician/article/228173/lung-cancer/pralsetinib-second-drug-ret-nsclc-approved-us